SC
IMNM icon

SummitTX Capital’s Immunome IMNM Stock Holding History

SummitTX Capital’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.03M Sell
92,880
-34,733
-27% -$773K 0.06% 302
2025
Q4 		$2.74M Buy
+127,613
New +$2.24M 0.08% 254
2025
Q3 		– Sell
-10,695
Closed -$99.5K – 862
2025
Q2 		$99.5K Sell
10,695
-10,181
-49% -$83.5K ﹤0.01% 716
2025
Q1 		$140K Buy
+20,876
New +$200K 0.01% 748

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

SummitTX Capital's IMNM Position: Q1 2026 in Review

SummitTX Capital reduced its Immunome (IMNM) stake by 27% in Q1 2026, selling an estimated $773K and leaving 92,880 shares worth $2.03M. The position accounts for 0.06% of the portfolio, ranked #302.

SummitTX Capital first reported a position in IMNM in Q1 2025 and has held it in 4 quarters since. The position peaked at $2.74M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • SummitTX Capital held 92,880 shares of Immunome worth $2.03M as of Q1 2026.
  • SummitTX Capital sold 34,733 Immunome shares in Q1 2026, an estimated $773K.
  • Immunome made up 0.06% of SummitTX Capital's portfolio in Q1 2026, its #302 holding.
  • SummitTX Capital first reported a position in Immunome in Q1 2025 and has held it in 4 quarters since.
  • SummitTX Capital's Immunome position peaked at $2.74M in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.